A phase 2/3 non-inferiority study compared de-escalation strategies to standard chemoradiation in patients with human ...

Bristol-Myers Squibb Company ( NYSE:BMY ) stock is about to trade ex-dividend in two days. The ex-dividend date is ...

Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...

Home-based phototherapy for plaque and guttate psoriasis is as effective as office-based phototherapy, results of the ...

Patients with a fast-spreading blood cancer respond well to outpatient treatment with CAR-T therapy, a new study found.

The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...

(Reuters) - Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene ...

Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...

Key Takeaways Bristol Myers Squibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration.The ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.